Zobrazeno 1 - 10
of 175
pro vyhledávání: '"Feighner JP"'
Autor:
Feighner Jp, Marilyn R. Morrissey, Alan Buffenstein, Edmund P. Harrigan, James Ferguson, William Jaffe, Paul E. Keck
Publikováno v:
Psychopharmacology. 140:173-184
A double-blind, placebo-controlled, multicenter study, was performed to evaluate the efficacy and safety of ziprasidone in 139 patients with an acute exacerbation of schizophrenia or schizoaffective disorder. Patients were randomized to receive zipra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce42302622e92c611e1993538a59b9b0
https://doi.org/10.1007/s002130050755
https://doi.org/10.1007/s002130050755
Autor:
Feighner Jp, J A Johnston, J Ferguson, M Ionescu-Pioggia, J Apter, B Samara, J Ascher, C Merideth, L Cunningham
Publikováno v:
Annals of Clinical Psychiatry. 6:153-160
Tricyclic antidepressant (TCA) medications are among the most widely used pharmacologic treatments for depression. However, a substantial number of patients fail to respond to these agents. Few standardized trials of pharmacologic treatments for TCA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9766a8c2eb931b9cf1bd4dc7829562ec
https://doi.org/10.3109/10401239409148997
https://doi.org/10.3109/10401239409148997
Publikováno v:
Psychopharmacology. 175(3)
Nemifitide is a novel peptide analog of melanocyte-inhibiting factor (MIF) that has been reported to relieve depressive symptoms in a very short period. The Flinders Sensitive Line (FSL) rat, a genetic animal model of depression with innate exaggerat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a339b23e72ac1cbb2b04055bc752706
https://pubmed.ncbi.nlm.nih.gov/14985919
https://pubmed.ncbi.nlm.nih.gov/14985919
Publikováno v:
Antidepressants: Past, Present and Future ISBN: 9783642621352
This chapter extends the discussion of novel mechanisms of action that may mediate antidepressant efficacy presented in the previous chapter and reviews findings concerning investigational antidepressants that are currently either in phase II or III
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f0de29711518b18bf48cbaf792d74457
https://doi.org/10.1007/978-3-642-18500-7_19
https://doi.org/10.1007/978-3-642-18500-7_19
Autor:
A. Patel, Abba J. Kastin, Joseph J. Hlavka, R.H Ehrensing, Feighner Jp, H. Abajian, Gabriela Nicolau, Lev Sverdlov, J.F. Noble
Publikováno v:
International clinical psychopharmacology. 16(6)
This study was designed to determine the safety, efficacy and pharmacokinetics of the antidepressant netamiftide (previously designated name: INN 00835) after 5 or 10 daily doses administered to patients diagnosed with major depression. Netamiftide w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ae7d7ad6b6e64c093033405b7f20e74
https://pubmed.ncbi.nlm.nih.gov/11712623
https://pubmed.ncbi.nlm.nih.gov/11712623
Autor:
Feighner Jp, Boyer Wf
Publikováno v:
International clinical psychopharmacology. 8(3)
Ipsapirone is a partial 5-HT1A, agonist which appears promising for the pharmacologic treatment of anxiety. In this four-week, double-blind, 19-center study, 249 outpatients with generalized anxiety disorder were randomized to one of four treatments:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4869ae2decf73b8fbb9673cd085de5d
https://pubmed.ncbi.nlm.nih.gov/7903326
https://pubmed.ncbi.nlm.nih.gov/7903326
Autor:
Feighner Jp
Publikováno v:
International clinical psychopharmacology. 6
Diagnostic criteria, random parallel placebo-controlled study design, and appropriate clinical assessment for both safety and efficacy are all among the essential requirements for the evaluation of a new antidepressant agent. Paroxetine and imipramin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::721a9cffe4d31160e9e71ca8a1ea4025
https://pubmed.ncbi.nlm.nih.gov/1431008
https://pubmed.ncbi.nlm.nih.gov/1431008
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.